(VIANEWS) – Shares of MDXHEALTH (BEL 20: MDXH.BR) fell by a staggering 26.93% in 10 sessions from €0.37 to €0.27 at 16:24 EST on Thursday, after three consecutive sessions in a row of losses. BEL 20 is falling 0.59% to €3,608.64, after five successive sessions in a row of losses.
MDXHEALTH’s last close was €0.28, 71.13% under its 52-week high of €0.97.
About MDXHEALTH
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Earnings Per Share
As for profitability, MDXHEALTH has a trailing twelve months EPS of €-0.282.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -156.7%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 114.4%, now sitting on 37.05M for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MDXHEALTH’s stock is considered to be overbought (>=80).
Volume
Today’s last reported volume for MDXHEALTH is 610395 which is 50.57% below its average volume of 414932.
Moving Average
MDXHEALTH’s value is way under its 50-day moving average of €0.50 and way below its 200-day moving average of €0.66.
More news about MDXHEALTH (MDXH.BR).
